TGF-β1–induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 3, 2016, Pages 791-800.e4

  Rawson, Renee ^a   Yang, Tom ^a   Newbury, Robert O ^a   Aquino, Melissa ^a   Doshi, Ashmi ^a   Bell, Braxton ^a   Broide, David H ^a   Dohil, Ranjan ^a   Kurten, Richard ^b   Aceves, Seema S ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Eosinophil; esophagitis; fibrosis; remodeling; SerpinE1; TGF 1

Indexed keywords

CELL PROTEIN; COLLAGEN TYPE 1; FIBRONECTIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EOSINOPHILIC ESOPHAGITIS; EPITHELIUM CELL; ESOPHAGUS BIOPSY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; CYTOLOGY; ESOPHAGUS; FIBROSIS; INFANT; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EOSINOPHILIC ESOPHAGITIS; EPITHELIAL CELLS; ESOPHAGUS; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INFANT; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84969584597     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.02.028     Document Type: Article

References (39)

1. 1 Liacouras, C.A., Furuta, G.T., Hirano, I., Atkins, D., Attwood, S.E., Bonis, P.A., et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128 (2011), 3–22.e6.
2. 2 Aceves, S.S., Ackerman, S.J., Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am 29 (2009), 197–211 xiii-xiv.
3. 3 Schoepfer, A.M., Safroneeva, E., Bussmann, C., Kuchen, T., Portmann, S., Simon, H.U., et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 145 (2013), 1230–1236 e1-2.
4. 4 Dellon, E.S., Kim, H.P., Sperry, S.L., Rybnicek, D.A., Woosley, J.T., Shaheen, N.J., A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 79 (2014), 577–585.e4.
5. 5 Aceves, S.S., Newbury, R.O., Dohil, R., Bastian, J.F., Broide, D.H., Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 119 (2007), 206–212.
6. 6 Aceves, S.S., Tissue remodeling in patients with eosinophilic esophagitis: what lies beneath the surface?. J Allergy Clin Immunol 128 (2011), 1047–1049.
7. 7 Straumann, A., Spichtin, H.P., Grize, L., Bucher, K.A., Beglinger, C., Simon, H.U., Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125 (2003), 1660–1669.
8. 8 Lucendo, A.J., Arias, A., De Rezende, L.C., Yague-Compadre, J.L., Mota-Huertas, T., Gonzalez-Castillo, S., et al. Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol 128 (2011), 1037–1046.
9. 9 Aceves, S.S., Newbury, R.O., Chen, D., Mueller, J., Dohil, R., Hoffman, H., et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 65 (2010), 109–116.
10. 10 Dohil, R., Newbury, R., Fox, L., Bastian, J., Aceves, S., Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 139 (2010), 418–429.
11. 11 Straumann, A., Conus, S., Degen, L., Frei, C., Bussmann, C., Beglinger, C., et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 9 (2011), 400–409.e1.
12. 12 Lieberman, J.A., Morotti, R.A., Konstantinou, G.N., Yershov, O., Chehade, M., Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy 67 (2012), 1299–1307.
13. 13 Abu-Sultaneh, S.M., Durst, P., Maynard, V., Elitsur, Y., Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci 56 (2011), 97–102.
14. 14 Assa'ad, A.H., Gupta, S.K., Collins, M.H., Thomson, M., Heath, A.T., Smith, D.A., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141 (2011), 1593–1604.
15. 15 Aceves, S.S., Chen, D., Newbury, R.O., Dohil, R., Bastian, J.F., Broide, D.H., Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol 126 (2010), 1198–1204.e4.
16. 16 Beppu, L., Yang, T., Luk, M., Newbury, R.O., Palmquist, J., Dohil, R., et al. MMPs-2 and -14 are elevated in eosinophilic esophagitis and reduced following topical corticosteroid therapy. J Pediatr Gastroenterol Nutr 61 (2015), 194–199.
17. 17 Beppu, L.Y., Anilkumar, A.A., Newbury, R., Dohil, R., Broide, D., Aceves, S., TGF-β1–induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis. J Allergy Clin Immunol 134 (2014), 1100–1107.e4.
18. 18 Blanchard, C., Mingler, M.K., McBride, M., Putnam, P.E., Collins, M.H., Chang, G., et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 1 (2008), 289–296.
19. 19 Abonia, J.P., Wen, T., Stucke, E.M., Grotjan, T., Griffith, M.S., Kemme, K.A., et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol 132 (2013), 378–386.
20. 20 Mishra, A., Wang, M., Pemmaraju, V.R., Collins, M.H., Fulkerson, P.C., Abonia, J.P., et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 134 (2008), 204–214.
21. 21 Cho, S., Kang, J., Lyttle, C., Harris, K., Daley, B., Grammer, L., et al. Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma. Ann Allergy Asthma Immunol 106 (2011), 371–377.
22. 22 Cho, S.H., Lee, S.H., Kato, A., Takabayashi, T., Kulka, M., Shin, S.C., et al. Cross-talk between human mast cells and bronchial epithelial cells in plasminogen activator inhibitor-1 production via transforming growth factor-beta1. Am J Respir Cell Mol Biol 52 (2015), 88–95.
23. 23 Lee, S.H., Eren, M., Vaughan, D.E., Schleimer, R.P., Cho, S.H., A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma. Am J Respir Cell Mol Biol 46 (2012), 842–846.
24. 24 Oh, C.K., Ariue, B., Alban, R.F., Shaw, B., Cho, S.H., PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294 (2002), 1155–1160.
25. 25 Cho, S.H., Hong, S.J., Chen, H., Habib, A., Cho, D., Lee, S.H., et al. Plasminogen activator inhibitor-1 in sputum and nasal lavage fluids increases in asthmatic patients during common colds. J Allergy Clin Immunol 133 (2014), 1465–1467 e1-2.
26. 26 Kowal, K., Bodzenta-Lukaszyk, A., Pampuch, A., Szmitkowski, M., Donati, M.B., Iacoviello, L., Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Immunol 144 (2007), 240–246.
27. 27 Nie, W., Li, B., Xiu, Q.Y., The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis. PLoS One, 7, 2012, e34385.
28. 28 Pampuch, A., Kowal, K., Bodzenta-Lukaszyk, A., Di Castelnuovo, A., Chyczewski, L., Donati, M.B., et al. The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. Allergy 61 (2006), 234–238.
29. 29 Schuliga, M., Westall, G., Xia, Y., Stewart, A.G., The plasminogen activation system: new targets in lung inflammation and remodeling. Curr Opin Pharmacol 13 (2013), 386–393.
30. 30 Aceves, S.S., Newbury, R.O., Dohil, M.A., Bastian, J.F., Dohil, R., A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann Allergy Asthma Immunol 103 (2009), 401–406.
31. 31 Wen, T., Stucke, E.M., Grotjan, T.M., Kemme, K.A., Abonia, J.P., Putnam, P.E., et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 145 (2013), 1289–1299.
32. 32 Abonia, J.P., Franciosi, J.P., Rothenberg, M.E., TGF-beta1: mediator of a feedback loop in eosinophilic esophagitis—or should we really say mastocytic esophagitis?. J Allergy Clin Immunol 126 (2010), 1205–1207.
33. 33 Kagalwalla, A.F., Akhtar, N., Woodruff, S.A., Rea, B.A., Masterson, J.C., Mukkada, V., et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol 129 (2012), 1387–1396.e7.
34. 34 Degryse, B., Neels, J.G., Czekay, R.P., Aertgeerts, K., Kamikubo, Y., Loskutoff, D.J., The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 279 (2004), 22595–22604.
35. 35 Czekay, R.P., Wilkins-Port, C.E., Higgins, S.P., Freytag, J., Overstreet, J.M., Klein, R.M., et al. PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol, 2011, 2011, 562481.
36. 36 Garg, N., Goyal, N., Strawn, T.L., Wu, J., Mann, K.M., Lawrence, D.A., et al. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost 8 (2010), 1847–1854.
37. 37 Huang, W.T., Vayalil, P.K., Miyata, T., Hagood, J., Liu, R.M., Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol 46 (2012), 87–95.
38. 38 Zhang, Y.P., Li, W.B., Wang, W.L., Liu, J., Song, S.X., Bai, L.L., et al. siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Acta Pharmacol Sin 33 (2012), 897–908.
39. 39 Ghosh, A.K., Vaughan, D.E., PAI-1 in tissue fibrosis. J Cell Physiol 227 (2012), 493–507.